METHOD FOR ESTIMATING RISK OF PROGRESSING NON-SMALL-CELL LUNG CANCER FOLLOWING SURGICAL MANAGEMENT Russian patent published in 2013 - IPC G01N33/53 G01N33/574 

FIELD: medicine.

SUBSTANCE: what is presented is a method for estimating a risk of progressing non-small-cell lung cancer (NSCLC) in the patients following surgical management. The amount of IgG autologous antobidies to native secretory mucin MUCl (anti-sMUCl AAT) in blood serum in the NSCLC patients before the surgical managements, 9-14 days after the operation and during the follow-up care. The anti-sMUCl AAT level in patient's blood serum is matched with a double value described by formula Nmax=X+a, wherein Nmax is an upper limit of distribution, X is an average level of anti-sMUCl AAT, a is 95% confidence range of distribution of the level of anti-sMUCl AAT in healthy donors. The unchanged initially high level of anti-sMUCl AAT (more than 2Nmax) or the increased initially low level of anti-sMUCl AAT (less than 2Nmax) to the value ≥ 2Nmax after the surgical operation is a prognostic of non-recurrent clinical course. The unchanged initially low level of anti-sMUCl AAT (less than 2Nmax) after the operation testifies to the presence of latent tumour centres or latent tumour dissemination.

EFFECT: invention provides the effective method for estimating a risk of progressing NSCLC in the patients after the surgical intervention enabling the adequate correction of a postoperative therapeutic approach and follow-up care.

5 dwg, 2 ex